Department of Pulmonary Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Department of Surgery, Utrecht University Medical Center, Utrecht, the Netherlands.
PLoS One. 2019 Mar 7;14(3):e0212952. doi: 10.1371/journal.pone.0212952. eCollection 2019.
Birt-Hogg-Dubé syndrome is associated with an increased risk for renal cell carcinoma. Surveillance is recommended, but the optimal imaging method and screening interval remain to be defined. The main aim of our study was to evaluate the outcomes of RCC surveillance to get insight in the safety of annual US in these patients. Surveillance data and medical records of 199 patients with Birt-Hogg-Dubé syndrome were collected retrospectively using medical files and a questionnaire. These patients were diagnosed in two Dutch hospitals and data were collected until June 2014. A first screening for renal cell carcinoma was performed in 172/199 patients (86%). Follow-up data were available from 121 patients. The mean follow-up period per patient was 4.2 years. Of the patients known to be under surveillance, 83% was screened at least annually and 94% at least every two years. Thirty-eight renal cell carcinomas had occurred in 23 patients. The mean age at diagnosis of the first tumour was 51. Eighteen tumours were visualized by ultrasound. Nine small tumours (7-27 mm) were visible on MRI or CT and not detected using ultrasound. Our data indicate that compliance to renal screening is relatively high. Furthermore, ultrasound might be a sensitive, cheap and widely available alternative for MRI or part of the MRIs for detecting clinically relevant renal tumours in BHD patients,but the limitations should be considered carefully. Data from larger cohorts are necessary to confirm these observations.
Birt-Hogg-Dubé 综合征与肾细胞癌风险增加相关。建议进行监测,但最佳的成像方法和筛查间隔仍有待确定。我们研究的主要目的是评估肾细胞癌监测的结果,以了解这些患者每年进行 US 的安全性。使用病历和问卷调查,回顾性地收集了 199 例 Birt-Hogg-Dubé 综合征患者的监测数据和医疗记录。这些患者在荷兰的两家医院被诊断出来,数据收集截至 2014 年 6 月。172/199 例(86%)患者进行了首次肾癌筛查。121 例患者可获得随访数据。每位患者的平均随访期为 4.2 年。已知正在接受监测的患者中,83%至少每年筛查一次,94%至少每两年筛查一次。23 例患者中发生了 38 例肾细胞癌。首次肿瘤诊断的平均年龄为 51 岁。18 个肿瘤通过超声显示。9 个小肿瘤(7-27 毫米)在 MRI 或 CT 上可见,而超声无法检测到。我们的数据表明,肾脏筛查的依从性相对较高。此外,超声可能是一种敏感、廉价且广泛可用的替代 MRI 或部分 MRI 的方法,用于检测 BHD 患者中具有临床意义的肾肿瘤,但应谨慎考虑其局限性。需要更大的队列数据来证实这些观察结果。